Horsham-based Myonex has appointed its chief financial officer, Greg Lavin, as the top executive of the clinical trial supply and services company, writes John George for the Philadelphia Business Journal.
Lavin will assume the role of CEO on January 1, succeeding James Lovett, who is retiring after six years in the position but will continue to serve on the company’s board.
Lavin was previously CFO of QPS Holdings, a clinical research organization in Newark, Delaware.
Myonex sources, packages, labels, stores, and distributes drugs and related supplies for clinical trials. Over the past six years, Lavin and Lovett collaborated on expanding the company into an integrated provider of clinical trial supply and commercial packaging services.
“Greg knows the industry, understands our clients, and shares our vision,” said Michael Cohen, executive chairman of Myonex. “His passion for Myonex’s opportunity in the marketplace will help build on our momentum.”
In 2021, Myonex completed a $20 million project to open its 65,000 square foot global headquarters in the Keith Valley Business Center in Horsham, relocating from its Norristown home. The new facility offers broader manufacturing and packaging capabilities along with additional freezer and cold storage areas.
Read more about Myonex in the Philadelphia Business Journal.
